Havlickuv Brod 1

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Researchers are conducting a national, prospective, multicenter observational pilot project in the Czech Republic focused on screening for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in patients after an episode of Acute Pulmonary Embolism (APE). The main aim is to develop, test, and implement a standardized procedure for early detection of CTEPH and ensure rapid referral to specialized centers treating this condition. Early detection and timely treatment are important to improve patients' quality of life and reduce the risk of complications or death. The study uses a standardized CTEPH screening protocol designed to identify patients after APE who may have or develop CTEPH. This includes implementing a uniform screening algorithm and optimizing the referral process to specialized pulmonary hypertension centers. The project plans to include around 500 patients across about 10 selected centers, focusing on validating the screening process and patient flow from cardiologists to pulmonary hypertension treatment centers. Participants will be followed for up to six months from enrollment. Researchers will assess the positive predictive value of the initial examination, the rate of detecting CTEPH, and how many patients with suspected CTEPH attend follow-up exams at specialized centers. The study involves monitoring patients' symptoms, risk factors, and screening outcomes to evaluate the effectiveness and feasibility of the screening approach.

Researchers are conducting a national, prospective, multicenter pilot project focused on following up children who were born prematurely and are now 5 years old. The main goal is to develop and test a national method for monitoring the development of these children to reduce negative effects on their overall growth and family life. This project aims to improve long-term care for premature infants by identifying developmental abnormalities early. Eligible children will receive a comprehensive pediatric check-up including vision screening using Plusoptix, speech and language tests (TEPO and TEPRO), as well as psychological (IDS-P), motor (MABC-2), and pulmonary (spirometry) evaluations. If any concerns arise during these assessments, children will be referred to specialists such as rehabilitation physicians, speech therapists, psychiatrists, or ophthalmologists. This structured evaluation is designed to support early detection and intervention. Participants will undergo these evaluations at 5 years of age, and researchers will track the proportion of children identified with developmental abnormalities and those referred to specialized centers during the study. The assessments include multiple developmental areas to provide a thorough understanding of each child's health status. The study is supported by national and European funding and has received ethical approval from multiple committees, ensuring careful oversight throughout the project.

Researchers are comparing two types of intraocular lenses (IOLs) for people with age-related cataracts: an extended depth of focus (EDF) lens and a monofocal lens. The study aims to assess the safety and effectiveness of the EDF AT LARA 829MP posterior chamber intraocular lens for correcting aphakia. Participants are adults aged 18 or older with clinically significant bilateral cataracts suitable for cataract surgery and IOL implantation. Participants will receive either the EDF intraocular lens or the monofocal intraocular lens during cataract surgery. The lenses are implanted in the posterior chamber of the eye. The study is randomized, controlled, and observer-masked, conducted across multiple centers. The trial evaluates visual acuity measures at various distances and defocus levels after implantation. During the study, participants will undergo assessments including monocular distance-corrected intermediate visual acuity at 66 cm, corrected distance visual acuity at 4 meters, distance-corrected visual acuity at 1 meter, and photopic distance-corrected visual acuity. These outcomes will be measured at 6 months post-implantation. Safety and effectiveness will be closely monitored throughout the trial, with adherence to scheduled visits and procedures as defined by the study protocol.